14 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
23688699	3	Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists.	University of Camerino
16250663	8	Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.	University of Bonn
20045645	66	Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.	Roche Palo Alto
22370269	44	Discovery of P2X3 selective antagonists for the treatment of chronic pain.	Astrazeneca
21207957	163	Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor.	University of Bonn
12213051	207	Purine and pyrimidine (P2) receptors as drug targets.	National Institute of Diabetes
19231180	81	Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.	Roche Palo Alto
19231178	61	Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.	Roche Palo Alto
11462975	50	Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.	National Institute of Diabetes and Digestive and Kidney Diseases
9632352	7	A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors.	National Institute of Diabetes and Digestive and Kidney Diseases
12798321	26	Nicotinyl aspartyl ketones as inhibitors of caspase-3.	Merck Frosst Canada
16570918	49	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.	Saarland University